Kevin Flaherty, MD
Pulmonary Disease · Ann Arbor, MINPI 1831271741
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $198,080 of the $327,961 with a category attached, or 60.4%. 20 manufacturers reported payments, led by Boehringer Ingelheim at 29.2% of the total. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $1154.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$96K
- Boehringer Ingelheim International GmbH$81K
- United Therapeutics Corporation$41K
- Boehringer Ingelheim RCV GmbH & Co KG$26K
- CSL Behring$20K
- Roche Products Limited$16K
- plus $49K from 14 others
Across 25 payments — averaging $79,391 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.9M
- F. Hoffmann-la Roche AG$27K
- Boehringer Ingelheim$10K
- Boehringer Ingelheim International GmbH$1K
What the payments were for
- Consulting fees$198,08060%
- Speaking & faculty fees$77,35424%
- Travel & lodging$48,40415%
- Food & beverage$4,1231%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 105 | $95,670 |
| Boehringer Ingelheim International GmbH | 85 | $81,301 |
| United Therapeutics Corporation | 42 | $40,511 |
| Boehringer Ingelheim RCV GmbH & Co KG | 7 | $25,779 |
| CSL Behring | 5 | $19,995 |
| Roche Products Limited | 5 | $16,148 |
| GSK | 6 | $13,706 |
| Merck | 10 | $6,578 |
| Amgen | 1 | $4,726 |
| Astrazeneca AB | 2 | $3,501 |
| Shionogi Inc | 3 | $3,053 |
| AbbVie | 2 | $2,835 |
| Boehringer Ingelheim Malaysia Sdn. Bhd. | 1 | $2,813 |
| Lupin Inc. | 1 | $2,655 |
| Boehringer Ingelheim Canada Ltd.ltee | 1 | $2,500 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,100 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $1,980 |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | 1 | $1,563 |
| Kowa Research Institute, Inc. | 1 | $300 |
| Genentech USA, Inc. | 2 | $249 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$138,287
- TYVASO$22,743
- NINTEDANIB$8,396
- KRYSTEXXA$4,726
- Esbriet$134
How this compares
$327,961 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 314 | $4,225,510 |
| Pirfenidone | 168 | $599,983 |
| EliquisApixaban | 27 | $31,249 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $19,262 |
| Tacrolimus | 85 | $8,415 |
| Mycophenolate Mofetil | 27 | $2,548 |
| Azathioprine | 39 | $1,872 |
| Omeprazole | 71 | $1,113 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $1,085 |
| Prednisone | 132 | $910 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 157 | $797 |
| Azithromycin | 54 | $670 |
| Atorvastatin Calcium | 27 | $420 |
| Acyclovir | 46 | $381 |
| Hydroxychloroquine Sulfate | 12 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $95,670 | $4,225,510314 claims |
| GSKTrelegy Ellipta | $13,706 | $19,26225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Ann Arbor
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Justin OldhamAnn Arbor$392K
- Jose de CardenasAnn Arbor$115K
- Timothy BlackwellAnn Arbor$99K
- Philip ChoiAnn Arbor$54K
- Jeanette BrownAnn Arbor$38K
- Jeffrey CurtisAnn Arbor$37K
- Vibha LamaAnn Arbor$26K
- Eric WhiteAnn Arbor$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.